Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.
You may also be interested in...
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small lung cancer